I. Opening Remarks – Refining our search for common ground?

II. Next Meeting (#4)

   Tuesday, October 23, 2017
   1 to 4PM
   MIA Hearing Room, 24th Floor
   200 St. Paul Place
   Baltimore, MD 21202

III. Specialty Drugs

   1) Should the definition of Specialty Drug be amended, specifically at § 15-847(a)(5)(ii) to recognize a higher cost than $600 for a 30 day supply?
      a. Is $1,000 high enough to make an impact?
      b. Is $2,500 too high?
      c. What are the impacts, if any, on premiums if the $600 amount is raised?

   2) What accreditation organizations other than URAC are there for specialty pharmacy?
      a. Joint Commission Accreditation, Accreditation Commission for Health Care, Community Health Accreditation Program, Center for Pharmacy Practice Accreditation (CPPA)
      b. Which if any of these other accreditations are potentially acceptable to Carriers, Plans, and Pharmacy Benefit Managers?
      c. What are the negatives or perceived issues with the other accreditations?

IV. Wrap Up